A 35-year-old man with a known history of atopic dermatitis presents with pruritus, erythema, and lichenification of the antecubital fossae and neck. He reports seasonal exacerbations and a family history of asthma and allergic rhinitis. Which investigation is most appropriate to confirm the underlying IgE-mediated mechanism and identify specific allergen sensitization?

Explanation

## Diagnosis of Atopic Dermatitis and IgE-Mediated Sensitization ### Clinical Presentation The patient presents with classic features of atopic dermatitis (AD): - Chronic pruritus and eczematous lesions - Predilection sites (antecubital fossae, neck) - Family history of atopy (asthma, allergic rhinitis) - Seasonal pattern suggesting environmental allergen involvement ### Why Serum Total and Allergen-Specific IgE is the Most Appropriate Investigation Here **Key Point:** The stem asks to *confirm the underlying IgE-mediated mechanism* AND *identify specific allergen sensitization*. Serum total IgE + allergen-specific IgE (ImmunoCAP/RAST) fulfils both objectives simultaneously, is non-invasive, and is safe to perform at any stage of disease — including during an active flare. **High-Yield:** Serum IgE testing: - Non-invasive; no risk of anaphylaxis or systemic reaction - Can be performed during acute flares or remission without modification - Quantitative (total IgE) and qualitative (specific IgE to individual allergens) - ImmunoCAP (fluorescence enzyme immunoassay) is the modern preferred method; RAST (radioallergosorbent test) is the older isotope-based predecessor - Elevated total IgE (> 150 IU/mL, often > 1000 IU/mL in severe AD) supports the atopic/Th2 phenotype - Specific IgE results guide allergen avoidance and allergen immunotherapy decisions ### Investigation Comparison | Investigation | Hypersensitivity Type | Timing Constraint | Safety | Primary Use | |---|---|---|---|---| | **Serum total + specific IgE (ImmunoCAP)** | Type I (IgE-mediated) | None — any time | Excellent | Confirm IgE mechanism; identify allergens; first-line in active AD | | Skin prick test (SPT) | Type I (IgE-mediated) | Avoid antihistamines; can be done outside acute flare | Good | Gold standard for allergen identification in stable patients | | Intradermal skin test | Type I (IgE-mediated) | Defer during acute flare; avoid antihistamines | Moderate (anaphylaxis risk) | Confirmation when SPT equivocal | | Patch testing | Type IV (contact/delayed) | 48–96 h reading | Good | Allergic contact dermatitis — NOT for Type I | | IgG subclass + complement | Type II/III | None | Excellent | Immune complex / cytotoxic disease — NOT for Type I | **Clinical Pearl:** Skin prick testing (SPT) is considered the gold standard for allergen identification in many international guidelines (EAACI, AAAAI) in *stable* patients. However, in a patient with *active* atopic dermatitis (as in this stem — ongoing pruritus, erythema, lichenification), serum IgE testing is the preferred first-line investigation because: (1) it can be performed safely during a flare, (2) dermographism and widespread eczema reduce SPT reliability, and (3) it simultaneously confirms the IgE-mediated mechanism. Intradermal testing carries a higher risk of systemic reactions and is deferred during active disease; it is not a substitute for SPT in routine allergen workup. ### Pathophysiology of Type I Hypersensitivity in AD ```mermaid flowchart TD A[Allergen exposure]:::outcome --> B[Th2 cell activation]:::outcome B --> C[IL-4 / IL-13 production]:::outcome C --> D[B cell class switching → IgE synthesis]:::action D --> E[IgE binds FcεRI on mast cells & basophils]:::outcome E --> F[Re-exposure: cross-linking → degranulation]:::urgent F --> G[Histamine, leukotrienes → pruritus, erythema, eczema]:::outcome H[Elevated serum total IgE + allergen-specific IgE]:::action -.->|Confirms mechanism| D ``` ### Why Other Options Are Incorrect - **Intradermal skin testing (B):** Useful for allergen identification in stable patients but carries anaphylaxis risk and is unreliable during active flares due to background skin inflammation and dermographism. It does not simultaneously confirm the IgE-mediated mechanism as a quantitative assay. - **Patch testing (C):** Designed for Type IV (T-cell mediated, delayed) contact hypersensitivity. It does not detect IgE-mediated sensitization and is irrelevant to the atopic mechanism described. - **IgG subclass + complement (D):** Relevant to Type II (cytotoxic) and Type III (immune complex) hypersensitivity. These markers would not be elevated in IgE-mediated atopic disease. [cite: Robbins & Cotran Pathologic Basis of Disease, 10e, Ch 6 — Diseases of the Immune System; EAACI/GA²LEN/EDF/WAO Atopic Dermatitis Guidelines]